TriNetX, the global health research network representing nearly 100 million patients, has developed a groundbreaking chemotherapy lines of treatment identification algorithm that understands treatment patterns to deduce the line of chemotherapy treatment a patient is undergoing. This information, up to now nearly impossible to obtain, is critical for biopharmaceutical companies striving to develop therapies for patients involved in care regimens beyond first line treatments.
Chemotherapy lines of treatment is the newest component of the industry-leading platform TriNetX has built to help researchers develop effective oncology clinical trial protocols and identify eligible patients. TriNetX is providing access to seamlessly integrated data from EMRs, tumor registries, unstructured pathology reports using natural language processing, and molecular genomics data. The TriNetX platform also predicts how many new patients will become eligible for a clinical trial in the next 12 months on a site by site basis.
Network members utilize TriNetX’s cloud-based, health research platform to analyze patient populations and perform “what-if” analyses in real-time. As members, healthcare organizations receive hardware and software that are configured within the organization’s IT infrastructure and often builds on existing data resources such as i2b2 and Observational Medical Outcomes Partnership (OMOP). Researchers then have access to the institution’s de-identified patient data through a user-friendly interface and a growing number of visualization and analysis capabilities.
Biopharmaceutical companies and CROs are presented with aggregate views, but each data point in the TriNetX network can be traced to healthcare organizations who have the ability to identify individual patients. This enables clinical researchers to develop virtual patient cohorts that can then be re-identified for potential recruitment into a clinical trial.
“Thousands of clinical trial protocols have been designed with the TriNetX platform,” said Matvey Palchuk, VP Informatics, TriNetX. “That experience is combined with an unparalleled understanding of the nuances of real world data, enabling TriNetX to innovate and answer the complex questions inherent to oncology clinical trials.”
